CARDIOVASCULAR SAFETY PROFILE OF PIOGLITAZONE ALONG WITH VITAMIN E
The increase incidence of obesity. stress and aging in genetically predisposed population has lead to an increase in the incidence of type 2 diabetes mellitus. This led to the development of new drugs such as thiazolidinediones (TZDs) which is a agonist of Peroxisome Proliferator-Activated Receptor (PPARgamma).Pioglitazone is a TZD Â have recently been identified for its severe cardiovasculara complication. Pioglitazone is oral hypoglycemic agent Â which has been shown to be effective Â by lowering insulin resistance.Due to its cardiovasculaqr risk factor it is combined with adjunct vitamin E,an antioxidantÂ in theÂ present study. The safety and efficacy of pioglitazone are increased several fold along with Â vitamin E.Keywords: Vitamin E,Pioglitazone, PPARÎ³, diabetes
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).